Interpace Biosciences Announces First Quarter 2025 Financial and Business Results
Interpace Biosciences (OTCQX: IDXG) reported strong financial results for Q1 2025, with revenue reaching $11.5 million, a 13% increase year-over-year. The company achieved record thyroid test revenue of $8.0M (up 19%) and record thyroid test volume (up 16%). Cash collections hit record levels at $11.3 million, up 10% from the previous year.
Key financial metrics showed significant improvement, with gross profit margin increasing to 64% from 62%, and income from continuing operations reaching $1.8 million, a $0.9 million improvement over Q1 2024. The company initiated full-year 2025 revenue guidance of approximately $38 million, despite the anticipated loss of PancraGEN revenue after May 2, 2025.
Interpace Biosciences (OTCQX: IDXG) ha riportato risultati finanziari solidi per il primo trimestre 2025, con un fatturato che ha raggiunto 11,5 milioni di dollari, registrando un aumento del 13% rispetto all'anno precedente. L'azienda ha raggiunto un fatturato record dai test tiroidei di 8,0 milioni di dollari (in crescita del 19%) e un volume record di test tiroidei (in aumento del 16%). Le riscossioni in contanti hanno toccato livelli record a 11,3 milioni di dollari, con un incremento del 10% rispetto all'anno precedente.
I principali indicatori finanziari hanno mostrato un miglioramento significativo, con un margine di profitto lordo salito al 64% dal 62%, e un reddito dalle operazioni continuative pari a 1,8 milioni di dollari, un miglioramento di 0,9 milioni rispetto al primo trimestre 2024. L'azienda ha fornito una previsione di fatturato per l'intero 2025 di circa 38 milioni di dollari, nonostante la prevista perdita dei ricavi di PancraGEN dopo il 2 maggio 2025.
Interpace Biosciences (OTCQX: IDXG) reportó sólidos resultados financieros para el primer trimestre de 2025, con ingresos que alcanzaron los 11,5 millones de dólares, un aumento del 13% interanual. La compañía logró ingresos récord por pruebas de tiroides de 8,0 millones de dólares (un 19% más) y un volumen récord de pruebas de tiroides (un 16% más). Las cobros en efectivo alcanzaron niveles récord de 11,3 millones de dólares, un 10% más que el año anterior.
Los principales indicadores financieros mostraron una mejora significativa, con un margen bruto que aumentó al 64% desde el 62%, y un ingreso por operaciones continuas de 1,8 millones de dólares, una mejora de 0,9 millones respecto al primer trimestre de 2024. La compañía inició una guía de ingresos para todo el año 2025 de aproximadamente 38 millones de dólares, a pesar de la pérdida anticipada de ingresos de PancraGEN después del 2 de mayo de 2025.
인터페이스 바이오사이언스(OTCQX: IDXG)는 2025년 1분기에 강력한 재무 실적을 보고했으며, 매출이 1,150만 달러에 달해 전년 대비 13% 증가했습니다. 회사는 갑상선 검사 매출에서 800만 달러(19% 증가)라는 기록을 세웠고, 갑상선 검사 건수도 16% 증가하며 최고치를 기록했습니다. 현금 수금액은 1,130만 달러로 전년 대비 10% 증가한 최고 수준을 달성했습니다.
주요 재무 지표도 크게 개선되어, 총이익률이 62%에서 64%로 상승했고, 계속 영업 이익은 180만 달러로 2024년 1분기 대비 90만 달러 증가했습니다. 회사는 2025년 연간 매출 가이던스를 약 3,800만 달러로 제시했으며, 2025년 5월 2일 이후 PancraGEN 매출 손실이 예상됨에도 불구하고 이 같은 전망을 내놓았습니다.
Interpace Biosciences (OTCQX : IDXG) a annoncé de solides résultats financiers pour le premier trimestre 2025, avec un chiffre d'affaires atteignant 11,5 millions de dollars, soit une augmentation de 13 % par rapport à l'année précédente. La société a réalisé un chiffre d'affaires record de 8,0 millions de dollars provenant des tests thyroïdiens (en hausse de 19 %) et un volume record de tests thyroïdiens (en hausse de 16 %). Les encaissements ont atteint des niveaux records à 11,3 millions de dollars, en hausse de 10 % par rapport à l'année précédente.
Les principaux indicateurs financiers ont montré une amélioration significative, avec une marge brute passant de 62 % à 64 %, et un résultat des opérations poursuivies atteignant 1,8 million de dollars, soit une amélioration de 0,9 million par rapport au premier trimestre 2024. La société a lancé une prévision de chiffre d'affaires pour l'ensemble de l'année 2025 d'environ 38 millions de dollars, malgré la perte anticipée des revenus de PancraGEN après le 2 mai 2025.
Interpace Biosciences (OTCQX: IDXG) meldete starke Finanzergebnisse für das erste Quartal 2025, mit einem Umsatz von 11,5 Millionen US-Dollar, was einer Steigerung von 13 % gegenüber dem Vorjahr entspricht. Das Unternehmen erzielte einen Rekordumsatz von 8,0 Millionen US-Dollar mit Schilddrüsentests (plus 19 %) und ein Rekordvolumen bei Schilddrüsentests (plus 16 %). Die Bareinnahmen erreichten mit 11,3 Millionen US-Dollar Rekordwerte, ein Anstieg von 10 % gegenüber dem Vorjahr.
Wichtige Finanzkennzahlen zeigten eine deutliche Verbesserung, wobei die Bruttogewinnmarge von 62 % auf 64 % stieg und der Gewinn aus fortgeführten Geschäftstätigkeiten 1,8 Millionen US-Dollar erreichte, eine Verbesserung um 0,9 Millionen US-Dollar gegenüber dem ersten Quartal 2024. Das Unternehmen gab eine Umsatzprognose für das gesamte Jahr 2025 von etwa 38 Millionen US-Dollar ab, trotz des erwarteten Wegfalls der PancraGEN-Umsätze nach dem 2. Mai 2025.
- Revenue increased 13% YoY to $11.5M
- Record thyroid test revenue up 19% YoY to $8.0M
- Record cash collections up 10% YoY to $11.3M
- Gross profit margin improved to 64% from 62%
- Income from continuing operations more than doubled to $1.8M
- Adjusted EBITDA increased to $2.1M from $1.2M
- Loss of PancraGEN revenue expected after May 2, 2025
| ● | Q1 Revenue of | |
| ● | Q1 Cash Collections of | |
| ● | Q1 Thyroid test volume up | |
| ● | Q1 Thyroid revenue of | |
| ● | Initiates Full Year 2025 Revenue Guidance of approximately | |
PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2025 and provided a business and financial update.
First quarter Net Revenue was
“Despite the uncertainty of PancraGEN reimbursement, Q1 2025 represented another quarter of year-over- year double digit volume and revenue growth,” stated Tom Burnell, President and CEO. “We are pleased with the Company’s continued growth in revenue, profitability and cash flow. These historical trends have established a new foundation and expectation for companies in the diagnostics industry and the patients they serve,” added Burnell.
First Quarter 2025 Financial Performance
For the First Quarter of 2025 as Compared to the First Quarter of 2024
| ● | Net Revenue was | |
| ● | Gross Profit percentage was | |
| ● | Operating income was | |
| ● | Income from continuing operations was | |
| ● | Adjusted EBITDA was | |
| ● | Q1 2025 cash collections totaled | |
About Interpace Biosciences
Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has three commercialized molecular tests and one test in a clinical evaluation program (CEP): ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay; ThyraMIR®v2, used in combination with ThyGeNEXT®, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification; and RespriDX®, that differentiates lung cancer of primary versus metastatic origin. In addition, BarreGEN®, a molecular-based assay that helps resolve the risk of progression of Barrett’s Esophagus to esophageal cancer, is currently in a CEP, whereby we gather information from physicians using BarreGEN to assist us in gathering clinical evidence relative to the safety and performance of the test and also providing data that will potentially support payer reimbursement.
For more information, please visit Interpace Biosciences’ website at www.interpace.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the possibility that the Company’s estimates of future revenue, cash flows and adjusted EBITDA may prove to be materially inaccurate, the Company’s prior history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s ability to repay borrowings from BroadOak, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect, and the Company’s ability to restructure itself in light of the loss of reimbursement for its PancraGEN product.
Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as amended, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts:
Investor Relations
Interpace Biosciences, Inc.
(855)-776-6419
Info@Interpace.com
INTERPACE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share data)
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenue, net | $ | 11,515 | $ | 10,178 | ||||
| Cost of revenue | 4,145 | 3,867 | ||||||
| Gross Profit | 7,370 | 6,311 | ||||||
| Sales and marketing | 2,814 | 2,821 | ||||||
| Research and development | 177 | 137 | ||||||
| General and administrative | 2,550 | 2,239 | ||||||
| Total operating expenses | 5,541 | 5,197 | ||||||
| Operating income | 1,829 | 1,114 | ||||||
| Interest accretion expense | - | (19 | ) | |||||
| Note payable interest | (78 | ) | (197 | ) | ||||
| Other income (expense), net | 21 | (82 | ) | |||||
| Income from continuing operations before tax | 1,772 | 816 | ||||||
| Provision for income taxes | 18 | 4 | ||||||
| Income from continuing operations | 1,754 | 812 | ||||||
| Loss from discontinued operations, net of tax | (107 | ) | (104 | ) | ||||
| Net income | $ | 1,647 | $ | 708 | ||||
| Basic income (loss) per share of common stock: | ||||||||
| From continuing operations | $ | 0.40 | $ | 0.19 | ||||
| From discontinued operations | (0.03 | ) | (0.02 | ) | ||||
| Net loss per basic share of common stock | $ | 0.37 | $ | 0.16 | ||||
| Diluted income (loss) per share of common stock: | ||||||||
| From continuing operations | $ | 0.06 | $ | 0.19 | ||||
| From discontinued operations | (0.00 | ) | (0.02 | ) | ||||
| Net loss per diluted share of common stock | $ | 0.06 | $ | 0.16 | ||||
| Weighted average number of common shares and | ||||||||
| common share equivalents outstanding: | ||||||||
| Basic | 4,420 | 4,370 | ||||||
| Diluted | 27,704 | 4,384 | ||||||
Selected Balance Sheet Data (Unaudited)
($ in thousands)
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Cash and cash equivalents | $ | 1,196 | $ | 1,461 | ||||
| Total current assets | 11,654 | 11,773 | ||||||
| Total current liabilities | 8,678 | 10,615 | ||||||
| Total assets | 14,494 | 14,792 | ||||||
| Total liabilities | 15,076 | 17,009 | ||||||
| Total stockholders' deficit | (582 | ) | (2,217 | ) | ||||
Selected Cash Flow Data (Unaudited)
($ in thousands)
| For the Three Months Ended | ||||||||
| March 31, | ||||||||
| 2025 | 2024 | |||||||
| Net income | $ | 1,647 | $ | 708 | ||||
| Net cash provided by (used in) operating activities | $ | 1,235 | $ | (58 | ) | |||
| Net cash used in investing activities | - | (28 | ) | |||||
| Net cash used in financing activities | (1,500 | ) | (600 | ) | ||||
| Change in cash and cash equivalents | (265 | ) | (686 | ) | ||||
| Cash and cash equivalents – beginning | 1,461 | 3,498 | ||||||
| Cash and cash equivalents – ending | $ | 1,196 | $ | 2,812 | ||||
Reconciliation of Adjusted EBITDA (Unaudited)
($ in thousands)
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2025 | 2024 | |||||||
| Income from continuing operations (GAAP Basis) | $ | 1,754 | $ | 812 | ||||
| Depreciation and amortization | 95 | 52 | ||||||
| Stock-based compensation | 15 | 79 | ||||||
| Severance expense | 168 | - | ||||||
| Taxes expense | 18 | 4 | ||||||
| Interest accretion expense | - | 19 | ||||||
| Note payable interest | 78 | 197 | ||||||
| Interest income | (7 | ) | (16 | ) | ||||
| Change in fair value of note payable | (25 | ) | 98 | |||||
| Adjusted EBITDA | $ | 2,096 | $ | 1,245 | ||||
Non-GAAP Financial Measures
In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.
In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock-based compensation, severance expense, interest and taxes, and other non-cash expenses including change in fair values of notes payable. The table above includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.
FAQ
What was Interpace Biosciences (IDXG) revenue in Q1 2025?
How much did IDXG's thyroid test revenue grow in Q1 2025?
What is Interpace Biosciences' revenue guidance for 2025?
How much was IDXG's income from continuing operations in Q1 2025?
What were Interpace Biosciences' cash collections in Q1 2025?
